Kiora Pharmaceuticals (KPRX) Non Operating Interest Expenses (2014 - 2022)

Kiora Pharmaceuticals (KPRX) has reported Non Operating Interest Expenses for 9 consecutive years, with $3451.0 the latest figure, recorded in Q4 2022.

• For the quarter ending Q4 2022, Non Operating Interest Expenses fell 16.48% year-over-year to $3451.0; the trailing twelve-month figure through Dec 2022 stood at $8520.0 (up 24.36% YoY), and the FY2025 full-year result was $19960.0, down 6.93% from the prior year.
• Non Operating Interest Expenses rose to $3451.0 in Q4 2022 per KPRX's latest filing, from $937.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $4186.0 in Q4 2020 and bottomed at $108.0 in Q1 2019.
• Historically, Non Operating Interest Expenses has averaged $1291.5 across 5 years, with a median of $304.0 in 2018.
• The sharpest annual moves came in 2018 and 2019: Non Operating Interest Expenses advanced 0.33% in 2018, then slumped 64.47% in 2019.
• Over 5 years, Non Operating Interest Expenses stood at $128.0 in 2018, then retreated by 14.84% to $109.0 in 2019, then surged by 3740.37% to $4186.0 in 2020, then fell by 1.29% to $4132.0 in 2021, then fell by 16.48% to $3451.0 in 2022.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $3451.0, $937.0, and $4132.0 for Q4 2022, Q3 2022, and Q4 2021 respectively.